Zacks Investment Research downgraded shares of BG MEDICINE INC (BGMD) from OUTPERFORM to NEUTRAL on May 20, 2013, with a target price of $2.00.
BG Medicine, Inc. operates as a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers. The Company is focused on the development of blood-based tests and other candidates for cardiovascular and other diseases. It seeks partnerships with leading diagnostic laboratory instrument manufacturers for the development and commercialization of its products. BG's product candidates include products for Cardiovascular Disease, Central Nervous System (CNS) and Autoimmune Disorders. BG Medicine, Inc. is headquartered in Waltham, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BG MEDICINE INC (BGMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment